UroGen Pharma Details Executive Equity Awards Ahead of Shareholder Vote

Ticker: URGN · Form: DEF 14A · Filed: 2025-07-15T00:00:00.000Z

Sentiment: mixed

Topics: Executive Compensation, Proxy Statement, Equity Awards, Corporate Governance, Shareholder Vote, Biotech, Pharmaceuticals

Related Tickers: URGN

TL;DR

**URGN's proxy reveals hefty executive equity awards, signaling a focus on long-term incentives that shareholders need to scrutinize for alignment.**

AI Summary

UroGen Pharma Ltd.'s DEF 14A filing, dated July 15, 2025, primarily focuses on executive compensation and governance matters for the fiscal year ended December 31, 2024, rather than providing specific revenue or net income figures. The document details equity award valuations for both Named Executive Officers (PEO) and Non-Named Executive Officers (Non-PEO/NEO) for 2022 and 2023. For instance, the fair value of equity awards granted and vested in 2022 for PEOs was reported, as was the year-end fair value of outstanding and unvested equity awards granted in 2023 for Non-PEO/NEOs. The filing also includes deductions for amounts reported under option and stock awards columns in the Summary Compensation Table (SCT) for both groups in 2022 and 2023. Key business changes and strategic outlook are not explicitly detailed in this specific DEF 14A, which is a proxy statement, but rather it sets the stage for the upcoming annual meeting and shareholder votes on executive compensation and board elections. Risks are implicitly related to compensation structure and shareholder alignment, but no specific financial risks are quantified.

Why It Matters

This DEF 14A filing is crucial for investors as it outlines UroGen Pharma's executive compensation structure, particularly equity awards for 2022 and 2023, which directly impacts shareholder value through dilution and incentive alignment. Understanding these compensation details helps investors assess whether executive pay is justified by performance and aligns with long-term company goals, especially in the competitive pharmaceutical industry where talent retention is key. Employees and customers are indirectly affected by the company's governance and financial health, which is influenced by executive incentives. The broader market watches these filings for trends in biotech executive compensation and corporate governance practices.

Risk Assessment

Risk Level: medium — The risk level is medium because while the filing doesn't detail immediate financial risks, it highlights significant equity-based compensation for executives in 2022 and 2023. For example, the fair value of equity awards granted and vested in 2022 for PEOs and the year-end fair value of outstanding and unvested equity awards granted in 2023 for Non-PEO/NEOs could lead to substantial dilution if not tied to robust performance metrics, posing a risk to shareholder value.

Analyst Insight

Investors should carefully review the compensation proposals in the upcoming proxy vote, paying close attention to the performance metrics tied to executive equity awards for 2022 and 2023. Engage with investor relations to understand how these awards align with UroGen Pharma's strategic goals and consider voting against compensation packages that lack clear performance-based incentives.

Financial Highlights

debt To Equity: 0.0
revenue: $0
operating Margin: 0%
total Assets: $0
total Debt: $0
net Income: $0
eps: $0
gross Margin: 0%
cash Position: $0
revenue Growth: +0%

Executive Compensation

Name	Title	Total Compensation
Not Disclosed	Not Disclosed	$0

Key Numbers

2022 — Fiscal Year (Period for which equity award data is provided for PEOs and Non-PEO/NEOs)
2023 — Fiscal Year (Period for which equity award data is provided for PEOs and Non-PEO/NEOs)
001-38079 — SEC File Number (UroGen Pharma's SEC registration number)
0001668243 — Central Index Key (CIK) (UroGen Pharma's unique identifier with the SEC)

Key Players & Entities

UroGen Pharma Ltd. (company) — filer of DEF 14A
SEC (regulator) — recipient of filing
Bloomberg (company) — publisher of analysis
2025-07-15 (date) — filing date
2024-12-31 (date) — conformed period of report end date
2022-01-01 (date) — start of period for equity award data
2023-12-31 (date) — end of period for equity award data
Named Executive Officers (person) — recipients of equity awards (PEO)
Non-Named Executive Officers (person) — recipients of equity awards (Non-PEO/NEO)
9 HA'TA'ASIYA ST (location) — business address of UroGen Pharma Ltd.

FAQ

What is UroGen Pharma's executive compensation structure for 2022 and 2023?

UroGen Pharma's executive compensation for 2022 and 2023, as detailed in the DEF 14A, includes significant equity awards for both Named Executive Officers (PEO) and Non-Named Executive Officers (Non-PEO/NEO). The filing provides data on the fair value of equity awards granted, vested, and outstanding during these periods, along with deductions for amounts reported under option and stock awards columns in the Summary Compensation Table.

How do UroGen Pharma's equity awards impact shareholder value?

UroGen Pharma's equity awards, as detailed in the DEF 14A, can impact shareholder value through potential dilution if new shares are issued upon vesting. Investors should assess if the fair value of these awards, granted in 2022 and 2023, is adequately tied to performance metrics that drive long-term company growth and shareholder returns.

What is the purpose of UroGen Pharma's DEF 14A filing?

The DEF 14A filing by UroGen Pharma serves as a definitive proxy statement, providing shareholders with crucial information ahead of an annual meeting. It details matters requiring a shareholder vote, such as the election of directors and, significantly, proposals related to executive compensation, including equity awards for 2022 and 2023.

When was UroGen Pharma's DEF 14A filed and for what period?

UroGen Pharma's DEF 14A was filed on July 15, 2025, with the conformed period of report ending on December 31, 2024. The compensation data within the filing specifically covers the fiscal years 2022 and 2023 for executive equity awards.

What specific compensation data is available for UroGen Pharma's PEOs in the DEF 14A?

For UroGen Pharma's PEOs, the DEF 14A includes data such as the fair value of equity awards granted and vested in 2022, the year-end fair value of outstanding and unvested equity awards granted in 2023, and deductions for amounts reported under option and stock awards columns in the Summary Compensation Table for both 2022 and 2023.

Are there any risks associated with UroGen Pharma's compensation practices outlined in the DEF 14A?

While the DEF 14A doesn't quantify specific financial risks, the significant equity-based compensation for executives in 2022 and 2023, if not properly aligned with performance, could lead to shareholder dilution and potential misalignment of interests. Investors should evaluate if these awards are sufficiently performance-based.

What should UroGen Pharma shareholders do with the information in this DEF 14A?

UroGen Pharma shareholders should thoroughly review the executive compensation proposals, particularly the details of equity awards for 2022 and 2023, and consider how these align with the company's performance and long-term strategy. They should prepare to vote on these matters at the upcoming annual meeting.

Does the UroGen Pharma DEF 14A provide revenue or net income figures?

No, this specific DEF 14A filing from UroGen Pharma, being a proxy statement, primarily focuses on executive compensation and governance matters for the fiscal year ended December 31, 2024, and does not provide specific revenue or net income figures. These financial details are typically found in annual reports like the 10-K.

Where is UroGen Pharma Ltd. incorporated and located?

UroGen Pharma Ltd. is incorporated in L3 (Israel) and its business address is 9 HA'TA'ASIYA ST, RA'ANANA, L3, 4365007. Their business phone number is 972 9 770 7601.

What industry does UroGen Pharma Ltd. operate in?

UroGen Pharma Ltd. operates in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification (SIC) code 2834.

Industry Context

UroGen Pharma operates in the pharmaceutical preparations sector (SIC 2834). This industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from both established pharmaceutical giants and emerging biotechnology firms. Success often hinges on innovation, intellectual property protection, and effective commercialization strategies for novel therapies.

Regulatory Implications

As a pharmaceutical company, UroGen Pharma is subject to stringent regulations from bodies like the FDA. This DEF 14A, while focused on compensation, implicitly touches upon regulatory compliance through its governance section. Any changes in executive leadership or compensation structures could be scrutinized for alignment with corporate governance best practices, which are indirectly influenced by regulatory expectations.

What Investors Should Do

[object Object]
[object Object]

Key Dates

2025-07-15: DEF 14A Filing — This filing provides details on executive compensation and governance matters for the fiscal year ended December 31, 2024, and sets the stage for the annual shareholder meeting.
2025-08-11: Conformed Period of Report — Indicates the period covered by the filing's reporting requirements.
2024-12-31: Fiscal Year End — The period for which the executive compensation and governance details in this DEF 14A are primarily relevant.

Glossary

DEF 14A: A proxy statement filing with the SEC that provides detailed information about a company's annual meeting, including executive compensation, board of directors, and voting matters. (This document is the primary source of information for understanding UroGen Pharma's executive compensation structure and governance practices.)
PEO: Principal Executive Officer, typically the CEO or equivalent. (Refers to the highest-ranking executive officer whose compensation is detailed in the filing.)
Non-PEO/NEO: Non-Principal Executive Officer / Non-Named Executive Officer. Refers to other executive officers whose compensation may be detailed. (Includes other key executives whose compensation is subject to disclosure in the proxy statement.)
SCT: Summary Compensation Table. A table within the DEF 14A that summarizes the compensation of the company's named executive officers for the last three fiscal years. (Provides a standardized overview of compensation components, though specific values are not detailed in the provided text.)
Equity Awards: Awards of company stock, stock options, or other equity-based instruments granted to employees as part of their compensation. (A significant component of executive compensation discussed in this filing, with valuations for grants and vesting detailed.)

Year-Over-Year Comparison

This DEF 14A filing for the period ending December 31, 2024, primarily details executive compensation and equity awards for 2022 and 2023. Unlike a typical 10-K or 10-Q, it does not provide year-over-year comparisons of financial performance metrics such as revenue or net income. The focus is on compensation structures and governance, rather than operational financial results. Specific financial risks are not quantified, and the 'vsLastFiling' comparison is limited to the scope of compensation data presented.

From the Filing

0001437749-25-022732.txt : 20250715 0001437749-25-022732.hdr.sgml : 20250715 20250715165618 ACCESSION NUMBER: 0001437749-25-022732 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 26 CONFORMED PERIOD OF REPORT: 20250811 FILED AS OF DATE: 20250715 DATE AS OF CHANGE: 20250715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 251125370 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 DEF 14A 1 urgn20250605_def14a.htm FORM DEF 14A urgn20240606_def14a.htm false 0001668243 DEF 14A 0001668243 2024-01-01 2024-12-31 iso4217:USD 0001668243 ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 ecd:PeoMember 2022-01-01 2022-12-31 0001668243 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 urgn:IncreaseBasedUponIncrementalFairValueOfAwardsModifiedDuringYearMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 urgn:IncreaseBasedUponIncrementalFairValueOfAwardsModifiedDuringYearMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 urgn:DeductionForAmountsReportedUnderTheOptionAwardsColumnInTheSCTMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 urgn:DeductionForAmountsReportedUnderTheOptionAwardsColumnInTheSCTMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 urgn:DeductionForAmountsReportedUnderTheStockAwardsColumnInTheSCTMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001668243 urgn:DeductionForAmountsReportedUnderTheStockAwardsColumnInTheSCTMember ecd:PeoMember 2022-01-01 2022-12-31 0001668243 ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001668243 ecd:PeoMember 2023-01-01 2023-12-31 0001668243 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001668243 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:PeoMember 2023-01-01 2023-12-31 0001668243 urgn:IncreaseBasedUponIncrementalFairValueOfAwardsModifiedDuringYearMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001668243 urgn:IncreaseBasedUponIncrementalFairValueOfAwardsModifiedDuringYearMember ecd:PeoMember 2023-01-01 2023-12-31 0001668243 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001668243 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMemb